Umit Tapan MD

Assistant Professor, Hematology & Medical Oncology

820 Harrison Ave | (617) 638-7523
Umit Tapan
Sections

Hematology & Medical Oncology

Centers

BU-BMC Cancer Center

Evans Center for Interdisciplinary Biomedical Research

Biography

Dr. Umit Tapan is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine and practicing Thoracic Oncologist at Boston Medical Center. His clinical interests are Non-small cell lung cancer, Small cell lung cancer, Mesothelioma, Immunotherapy, Targeted therapy/Precision Medicine. His research interests include Circulating tumor DNA, Gut microbiome and Cancer Immunotherapy, Racial Disparities in Cancer Care and Outcomes.

Dr. Tapan completed his fellowship in Hematology & Oncology at Boston Univesity Medical Center, in which he was Chief Fellow in Hematology & Oncology. Dr. Tapan completed his internship and residency at Steward Carney Hospital. He earned his medical degree from Hacettepe University School of Medicine, Ankara, Turkey.

Education

MD, Hacettepe University

Publications

Published on 3/10/2026

Kim JY, Dirks A, Ford RM, Pai L, Ludwig C, Tapan U. How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups. PLOS Digit Health. 2026 Mar; 5(3):e0001262. PMID: 41805924.

Published on 1/24/2026

Martinez CB, Bhatt S, Battaglini J, Beckett A, Tapan U. Lung Cancer in the Incarcerated Population: A Narrative Review. Curr Oncol Rep. 2026 Jan 24; 28(1):2. PMID: 41579227.

Published on 1/3/2026

Battaglini J, AlDoughaim M, Li K, Patel J, Bhatt S, Everett P, Oxnard GR, Tapan U. Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer. Clin Transl Oncol. 2026 Jun; 28(6):2428-2434. PMID: 41484568.

Published on 9/1/2025

Wang J, Sajeev G, Chai X, Takundwa R, Dirnberger F, Pundole X, Pastel M, Yang H, Tapan U. Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer. Oncologist. 2025 Sep 01; 30(9). PMID: 40839303.

Published on 8/29/2025

Shah MV, Solem CT, Liao A, Bell KF, Wang Y, Yang H, Meng Y, Ye M, Tapan U. Patient and Physician Preferences for Maintenance Treatment in Advanced Non-Small Cell Lung Cancer: Insights into Treatment Selection. Adv Ther. 2025 Nov; 42(11):5499-5514. PMID: 40879895.

Published on 4/15/2025

Shah MV, Solem CT, Bell KF, Aziez A, Sun X, Du M, Du EX, Yang H, Wang H, Hua Q, Tapan U. Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer. Adv Ther. 2025 Jun; 42(6):2782-2796. PMID: 40232624.

Published on 3/10/2025

Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.

Published on 9/9/2024

Murphy JF, Amin LB, Celikkaleli ST, Brown HE, Tapan U. Disparities in cancer care in individuals with severe mental illness: A narrative review. Cancer Epidemiol. 2024 Dec; 93:102663. PMID: 39255550.

Published on 12/29/2023

Burns L, Tukachinsky H, Raskina K, Huang RSP, Schrock AB, Sands J, Kulke MH, Oxnard GR, Tapan U. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma. Lung Cancer. 2024 Feb; 188:107454. PMID: 38159439.

Published on 12/12/2023

Dudipala H, Burns L, Jani CT, Radwan A, Al Omari O, Patel M, Kilic S, Zhao J, Mak K, Suzuki K, Tapan U. Disparities in Lung Cancer Clinical Trial Discussion and Enrollment at a Safety Net Hospital. Community Health Equity Res Policy. 2023 Dec 12; 2752535X231221394. PMID: 38087807.

View full list of 42 publications.